Iron Triangle Partners LP Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Iron Triangle Partners LP has acquired a new stake in Alnylam Pharmaceuticals, purchasing 65,409 shares valued at approximately $17.66 million, making it the firm's 16th largest holding.
• Alnylam Pharmaceuticals recently reported an earnings per share (EPS) of $0.32 for the quarter, significantly exceeding expectations and marking a 17.3% year-over-year revenue increase.
• Research analysts have a consensus rating of "Moderate Buy" for Alnylam Pharmaceuticals, with an average price target of $405.33 per share, indicating positive sentiment among experts.

Iron Triangle Partners LP purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 65,409 shares of the biopharmaceutical company's stock, valued at approximately $17,662,000. Alnylam Pharmaceuticals comprises 2.8% of Iron Triangle Partners LP's investment portfolio, making the stock its 16th largest position. Iron Triangle Partners LP owned 0.05% of Alnylam Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in ALNY. Vanguard Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock worth $3,525,544,000 after purchasing an additional 323,206 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in Alnylam Pharmaceuticals in the 1st quarter valued at approximately $69,292,000. Price T Rowe Associates Inc. MD increased its position in Alnylam Pharmaceuticals by 5.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock valued at $946,466,000 after acquiring an additional 185,783 shares during the period. GAMMA Investing LLC increased its position in Alnylam Pharmaceuticals by 30,759.4% in the 1st quarter. GAMMA Investing LLC now owns 166,332 shares of the biopharmaceutical company's stock valued at $44,913,000 after acquiring an additional 165,793 shares during the period. Finally, Orbimed Advisors LLC increased its position in Alnylam Pharmaceuticals by 66.0% in the 4th quarter. Orbimed Advisors LLC now owns 415,600 shares of the biopharmaceutical company's stock valued at $97,795,000 after acquiring an additional 165,300 shares during the period. Institutional investors own 92.97% of the company's stock.

Analyst Ratings Changes

Several analysts recently commented on the company. Truist Financial assumed coverage on Alnylam Pharmaceuticals in a research report on Monday, July 21st. They issued a "buy" rating and a $385.00 target price on the stock. BMO Capital Markets raised their target price on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an "outperform" rating in a research report on Tuesday, June 24th. Jefferies Financial Group increased their price target on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a "buy" rating in a research note on Monday, July 7th. UBS Group increased their price target on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Finally, Piper Sandler increased their price target on Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the company an "overweight" rating in a research note on Friday, August 1st. Twenty-two research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $412.79.

Alnylam Pharmaceuticals Stock Up 0.2%

NASDAQ:ALNY traded up $0.69 during trading hours on Tuesday, hitting $447.20. 844,119 shares of the stock traded hands, compared to its average volume of 957,091. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $469.81. The firm has a market cap of $58.62 billion, a price-to-earnings ratio of -181.05 and a beta of 0.32. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The firm has a 50 day moving average price of $377.23 and a 200 day moving average price of $304.58.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. During the same quarter in the prior year, the business earned ($0.13) EPS. The company's revenue for the quarter was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Pushkal Garg sold 1,455 shares of the company's stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $458.41, for a total value of $666,986.55. Following the transaction, the executive vice president directly owned 20,221 shares of the company's stock, valued at approximately $9,269,508.61. This represents a 6.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Dennis A. Ausiello sold 31,448 shares of the stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the transaction, the director directly owned 911 shares in the company, valued at $397,724.38. The trade was a 97.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 57,594 shares of company stock valued at $25,551,456 in the last three months. Company insiders own 1.20% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.